Drugs Made in America Acquisition Corp. (NASDAQ:DMAAU – Get Free Report) was the target of a large decrease in short interest during the month of August. As of August 14th, there was short interest totaling 1 shares, a decrease of 99.9% from the July 30th total of 884 shares. Based on an average daily volume of 143 shares, the short-interest ratio is currently 0.0 days.
Drugs Made in America Acquisition Stock Performance
Shares of Drugs Made in America Acquisition stock remained flat at $10.79 during trading on Tuesday. Drugs Made in America Acquisition has a 12-month low of $10.30 and a 12-month high of $12.50. The company’s 50-day moving average price is $10.80 and its 200-day moving average price is $10.70.
About Drugs Made in America Acquisition
Drugs Made in America Acquisition Corp is a special purpose acquisition company incorporated in Delaware and traded on the NASDAQ under the ticker DMAAU. It was organized to raise capital through its initial public offering and to identify and complete a business combination with one or more U.S.-based pharmaceutical or biotechnology companies.
The company’s investment mandate is focused on target businesses engaged in the development, manufacture or commercialization of finished dosage pharmaceuticals, active pharmaceutical ingredients and related medical products for the American market.
See Also
- Five stocks we like better than Drugs Made in America Acquisition
- Pathward’s Credit Scare Tests Its Comeback Story
- Wiring the AI Boom: Rumble’s $13.7B Pivot
- StoneX: Too Far Too Fast?
- DICK’s Sporting Goods Faces Pain Now for a Bigger Prize
Receive News & Ratings for Drugs Made in America Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Drugs Made in America Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
